In this review:
Tecentriq® (atezolizumab) is a humanised, engineered, IgG1 monoclonal antibody targeting programmed death ligand-1 (PD-L1). In New Zealand, atezolizumab is indicated (but not funded), in combination with nab-paclitaxel, for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥1%, and who have not received prior chemotherapy for metastatic disease.1 The aim of this review is to describe important safety and efficacy data for atezolizumab in patients with advanced TNBC. This publication has been commissioned by Roche Products (New Zealand) Limited.
Please login below to download this issue (PDF)